tirzepatide going off market FDA says this weight loss drug shortage is over, but patients worry about cost and availability The Ozempic-like obesity drugs create

Active Ingredient: Lactobacillus fermentum ME-3 (8 billion CFU) Other Ingredients: Maltodextrin, magnesium salts of fatty acids (anti-caking agent), vegetable capsule (hydroxypropylmethylcellulose)

Interestingly, GLP-1 receptor agonists, a class of drugs that includes Tirzepatide, have been found to cross the blood-brain barrier, where they may exert protective effects on neurons

Offering weight loss financing provides significant advantages for healthcare providers: Increases case acceptance for weight loss procedures Expands access to patients with high deductibles or partial insurance coverage Reduces financial objections during pricing discussions Improves revenue predictability through third-party lender payments Strengthens patient relationships by offering transparent, flexible options As demand for medical weight loss continues to grow, practices that provide accessible financing position themselves as patient-centered, responsive, and prepared to meet evolving financial realities

Because skincare is not just a daily routine

Clinical Takeaways As the prevalence of obesity, insulin resistance, metabolic syndrome and associated health complications continue to rise, targeting GLP-1 activity has emerged as a promising strategy in improving cardiometabolic health and encouraging sustainable weight loss

The primary competitive concern is whether its modest incremental weight loss advantage over tirzepatide (the current standard) justifies its differentiated side effect profile, particularly if glucagon agonism increases bone turnover, hepatic glucose production at higher doses, or cardiovascular risk